Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-08-11
1996-03-05
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530324, A61K 3800, C07K 200, C12P 2100, G01N 3353
Patent
active
054968003
ABSTRACT:
A process is provided for purifying Urogenital Sinus Derived Growth Inhibitory Factor (UGIF) from embryonic tissue which comprises chromatographing medium from cultures or culture-derived spheroids of embryonic tissue derived from the urogenital sinus by gel filtration chromatography. Further purification by reverse phase high pressure liquid chromatography is also demonstrated. The UGIF is obtained in 70-fold to 8000-fold purification over the conditioned medium. A UGIF composition of matter is also provided, as is a method for treating neoplasia with UGIF.
REFERENCES:
patent: 1163538 (1915-12-01), Hieatzman et al.
patent: 1651770 (1927-12-01), Hartmann
patent: 1690932 (1928-04-01), Hartmann
patent: 3008878 (1961-11-01), Keck
patent: 3409605 (1968-11-01), Florini
patent: 3867363 (1975-02-01), Hansen
patent: 3901870 (1975-08-01), Haupt et al.
patent: 4108849 (1978-08-01), Thomas
patent: 4510131 (1985-04-01), Donahoe et al.
patent: 4708948 (1987-11-01), Iwata et al.
patent: 5196334 (1993-03-01), Rowley
Johnson et al., Cancer Treatment Reviews, 2, 1-31, 1975.
Cunha, G. R., et al. Cell Differentiation 17:137-148 (1985).
Lasnitski, I., Animal Cell Culture (Freshney, R. I. ed., IRL Press, 1986) pp. 149-181.
Rowley, D. R., In Vitro Cell Dev. Biol. 28A:29-38 (1992).
Pretlow, T. G., et al., Cancer Research 51:3814-3817 (1991).
Harel, et al., Journal of Cellular Physiology 119:101-106 (1984).
Hsu, et al., Proc. Natl. Acad. Sci. USA 81:2107-2111 (1984).
Roberts, et al., Proc. Natl. Acad. Sci. USA 82:119-123 (1985).
Rowley, et al., Cancer Research 47:2955-2960 (1987).
Sporn, et al., Science 233:532-534 (1986).
Steck, et al., The Journal of Cell Biology 92:523-523 (1982).
Wang, et al., TIBS 11:24-26.
Wells, et al., Journal of Cellular Physiology 117:148-154 (1983).
Konig, et al., Urological Research 15:145-149 (1987).
Dai & Gupta, J. Biological Chemistry, 265(32):19871-19877 (1990).
Ijzermans & Marquet, Immunobiol, 179:456-473 (1989).
Quelle & Wojchowski, J. Biol. Chem. 266(1):609-614 (1991).
Ulich, et al., Experimental Hematology, 19:29-34 (1991).
Johnson, et al., Cancer Treatment Reviews 2:1-31 (1975).
Baird, et al., J. Cell Biochem Suppl. vol. O, No. 11, Part A, p. 50 (1987).
Rowley, D. R., Mol. and Cellular Biol. of Prostate Cancer (Karr, J. P., ed., Plenum Press, N.Y., 1991).
Rowley, D. R., Endocrinology 131:471-478 (1992).
Kimchi, A., et al., Science 240:196 (1988).
Baylor College of Medicine
Touzeau Lynn
Warden Jill
LandOfFree
Growth inhibitory factor from urogenital sinus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth inhibitory factor from urogenital sinus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth inhibitory factor from urogenital sinus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1413009